References
- Hicks R J, MacManus M P, Seymour J F. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005; 35: 165–175
- Kasamon Y L, Jones R J, Wahl R L. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 2007; 48(Suppl 1)19S–27S
- Shields A F, Grierson J R, Dohmen B M, Machulla H J, Stayanoff J C, Lawhorn-Crews J M, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4: 1334–1336
- Mier W, Haberkorn U, Eisenhut M. [18F]FLT; portrait of a proliferation marker. Eur J Nucl Med Mol Imag 2002; 29: 165–169
- Buck A K, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003; 44: 1426–1431
- Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma 2007; 48: 746–753
- Wagner M, Seitz U, Buck A, Neumaier B, Schultheiss S, Bangerter M, et al. 3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003; 63: 2681–2687
- Buck A K, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006; 66: 11055–11061
- Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35: 186–196
- Dittmann H, Dohmen B M, Paulsen F, Eichhorn K, Eschmann S M, Horger M, et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imag 2003; 30: 1407–1412
- Cobben D C, Elsinga P H, Hoekstra H J, Suurmeijer A J, Vaalburg W, Maas B, et al. Is 18F-3′-fluoro-3′-deoxy-l-thymidine useful for the staging and restaging of non-small cell lung cancer?. J Nucl Med 2004; 45: 1677–1682
- van Westreenen H L, Cobben D C, Jager P L, van Dullemen H M, Wesseling J, Elsinga P H, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 2005; 46: 400–404
- Hicks R J. The evolving role of fluorodeoxyglucose positron emission tomography (FDG PET) in lymphoma: how do we reconcile conflicting results in the era of evidence-based medicine?. Leuk Lymphoma 2006; 47: 2008–2010
- Blum R H, Seymour J F, Wirth A, MacManus M, Hicks R J. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2003; 4: 43–49
- Shipp M A, Ross K N, Tamayo P, Weng A P, Kutok J L, Aguiar R C, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74
- van Waarde A, Cobben D C, Suurmeijer A J, Maas B, Vaalburg W, de Vries E F, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004; 45: 695–700
- Zijlstra J M, Lindauer-van der Werf G, Hoekstra O S, Hooft L, Riphagen I I, Huijgens P C, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91: 522–529
- Lowe V J, Fletcher J W, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16: 1075–1084
- Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi Y E, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 4643–4651
- Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 2006; 24: 146–150
- Loi S, Michael M, Thompson M, Hicks R J, Mitchell P L, Ellis A, Milner A D, et al. Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. Br J Cancer 2005; 92: 655–661
- Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007, pre-published on-line